🇺🇸 Intrathecal cytarabine in United States

6 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 6

Most-reported reactions

1. Brain Oedema — 1 report (16.67%)
2. Pancreatitis — 1 report (16.67%)
3. Pulmonary Embolism — 1 report (16.67%)
4. Subarachnoid Haemorrhage — 1 report (16.67%)
5. Tachypnoea — 1 report (16.67%)
6. Thrombosis — 1 report (16.67%)

Source database →

Frequently asked questions

Is Intrathecal cytarabine approved in United States?

Intrathecal cytarabine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Intrathecal cytarabine in United States?

SWOG Cancer Research Network is the originator. The local marketing authorisation holder may differ — check the official source linked above.